Citations

Clear

959 citation(s) found for "Service, F J".

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
Pianko, Matthew J. , Funt, Samuel A. , Page, David B. , Cattry, Deepika, Scott, Emma C. , Ansell, Stephen M. , Borrello, Ivan , Gutiérrez, Martín , Lendvai, Nikoletta , Hassoun, Hani , Lesokhin, Alexander M. , Landgren, C Ola , Lesokhin, Alexander M , Landgren, Ola

Mayo Clinic

Leukemia & Lymphoma | May 30, 2017 | Volume: 59 | Issue: 1 | Pages: 221-224

10.1080/10428194.2017.1320713 | PMID 28554253 Get It

Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi‐Klug, Rose , Braffett, Barbara H. , White, Neil H. , Sherwin, Robert S., Service, F. John, Lachin, John M. , Tamborlane, William V. , Gubitosi-Klug, Rose A

Mayo Clinic

Diabetes Care | May 27, 2017 | Volume: 40 | Issue: 8 | Pages: 1010-1016

10.2337/dc16-2723 | PMID 28550194 Get It

OBJECTIVE During the Diabetes Control and Complications Trial (DCCT), intensive diabetes therapy achieving a mean HbA1c of ∼7% was associated with a threefold increase in the rate of severe hypoglycemia (defined as requiring assistance) compared with conventional diabetes therapy with a mean HbA1c of 9% (61.2 vs. 18.7 per 100 patient-years). After ∼30 years of follow-up, we investigated the rates of severe hypoglycemia in the DCCT/Epidemiology of Diabetes Inverventions and Complications (EDIC) cohort. RESEARCH DESIGN AND METHODS Rates of severe hypoglycemia were reported quarterly during DCCT and annually during EDIC (i.e., patient recall of episodes in the preceding 3 months). Risk factors influencing the rate of severe hypoglycemia over time were investigated. RESULTS One-half of the DCCT/EDIC cohort reported episodes of severe hypoglycemia. During EDIC, rates of severe hypoglycemia fell in the former DCCT intensive treatment group but rose in the former conventional treatment group, resulting in similar rates (40.8 vs. 36.6 episodes per 100 patient-years, respectively) with a relative risk of 1.12 (95% CI 0.91–1.37). A preceding episode of severe hypoglycemia was the most powerful predictor of subsequent episodes. Entry into the DCCT study as an adolescent was associated with an increased risk of severe hypoglycemia, whereas insulin pump use was associated with a lower risk. Severe hypoglycemia rates increased with lower HbA1c similarly among participants in both treatment groups. CONCLUSIONS Rates of severe hypoglycemia have equilibrated over time between the two DCCT/EDIC treatment groups in association with advancing duration of diabetes and similar HbA1c levels. Severe hypoglycemia persists and remains a challenge for patients with type 1 diabetes across their life span.
Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized Controlled Trial
Nelson, Gregg , Ramírez, Pedro T. , Ljungqvist, Olle , Dowdy, Sean C. , Nelson, Gregg S

Mayo Clinic

Obstetrics & Gynecology | May 24, 2017 | Volume: 129 | Issue: 6 | Pages: 1139-1139

10.1097/aog.0000000000002083 | PMID 28538481 Get It

Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV
Velázquez-Salinas, Lauro , Naik, Shruthi , Pauszek, Steven J. , Peng, Kah-Whye , Russell, Stephen J. , Rodrı́guez, Luis L. , Russell, Stephen J

Mayo Clinic

Human Gene Therapy Clinical Development | May 18, 2017 | Volume: 28 | Issue: 2 | Pages: 108-115

10.1089/humc.2017.015 | PMID 28514874 Get It

Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Respondek, Gesine , Kurz, Carolin , Arzberger, Thomas, Compta, Yaroslau , Englund, Elisabet , Ferguson, Leslie W. , Gelpí, Ellen , Irwin, David J. , Meissner, Wassilios G. , Pantelyat, Alexander , Rajput, Alex, Swieten, John C. van, Troakes, Claire , Josephs, Keith A. , Lang, Anthony E. , Mollenhauer, Brit , Müller, Ulrich , Whitwell, Jennifer L. , Antonini, Angelo , Bhatia, Kailash P. , Bordelon, Yvette , Corvol, Jean‐Christophe , Dodel, Richard , Kassubek, Jan , Krismer, Florian , Xiong, Chengjie , Lorenzl, Stefan , Morris, Huw R. , Nestor, Peter J. , Oertel, Wolfgang H., Rabinovici, Gil D. , Rowe, James B. , Eimeren, Thilo van , Wenning, Gregor K. , Boxer, Adam L. , Golbe, Lawrence I. , Litvan, Irene , Stamelou, María , Höglinger, Günter U. , Group, for the Movement Disorder Society‐Endorsed PSP Study, Meissner, Wassilios G , Bhatia, Kailash P , Stamelou, Maria , Höglinger, Günter U , Giese, Armin , Nilsson, Christer F. , Swieten, John C. van , Colosimo, Carlo , Grossman, Murray , Krismer, Florian , Group, for the Movement Disorder Society‐Endorsed PSP Study, Lang, Anthony E , Irwin, David J , Antonini, Angelo , Rowe, James B , Corvol, Jean-Christophe , Litvan, Irene , Xiong, Chengjie , Gelpi, Ellen , Pantelyat, Alex , Rabinovici, Gil D , Troakes, Claire , Morris, Huw R , van Eimeren, Thilo

Mayo Clinic

Movement Disorders | May 13, 2017 | Volume: 32 | Issue: 7 | Pages: 995-1005

10.1002/mds.27034 | PMID 28500752 Get It

ABSTRACTBackgroundProgressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes.ObjectiveTo identify clinical features and investigations that predict or exclude PSP pathology during life, aiming at an optimization of the clinical diagnostic criteria for PSP.MethodsWe performed a systematic review of the literature published since 1996 to identify clinical features and investigations that may predict or exclude PSP pathology. We then extracted standardized data from clinical charts of patients with pathologically diagnosed PSP and relevant disease controls and calculated the sensitivity, specificity, and positive predictive value of key clinical features for PSP in this cohort.ResultsOf 4166 articles identified by the database inquiry, 269 met predefined standards. The literature review identified clinical features predictive of PSP, including features of the following 4 functional domains: ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction. No biomarker or genetic feature was found reliably validated to predict definite PSP. High‐quality original natural history data were available from 206 patients with pathologically diagnosed PSP and from 231 pathologically diagnosed disease controls (54 corticobasal degeneration, 51 multiple system atrophy with predominant parkinsonism, 53 Parkinson's disease, 73 behavioral variant frontotemporal dementia). We identified clinical features that predicted PSP pathology, including phenotypes other than Richardson's syndrome, with varying sensitivity and specificity.ConclusionsOur results highlight the clinical variability of PSP and the high prevalence of phenotypes other than Richardson's syndrome. The features of variant phenotypes with high specificity and sensitivity should serve to optimize clinical diagnosis of PSP. © 2017 International Parkinson and Movement Disorder Society
Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses
Bào, Yīmíng , Basler, Christopher F. , Bavari, Sina , Bukreyev, Alexander , Chandran, Kartik , Dolnik, Olga , Dye, John M. , Ebihara, Hideki , Formenty, Pierre , Hewson, Roger , Kobinger, Gary , Leroy, Eric M. , Mühlberger, Elke , Sv, Netesov , Patterson, Jean L. , Smither, Sophie J. , Takada, Ayato , Volchkov, Viktor E. , Wahl‐Jensen, Victoria , Kuhn, Jens H. , Amarasinghe, Gaya K. , Paweska, Janusz Tadeusz , Towner, Jonathan S. , Ebihara, Hideki , Mühlberger, Elke

Mayo Clinic

Viruses | May 11, 2017 | Volume: 9 | Issue: 5 | Pages: 106

10.3390/v9050106 | PMID 28492506 Get It

The mononegaviral family Filoviridae has eight members assigned to three genera and seven species. Until now, genus and species demarcation were based on arbitrarily chosen filovirus genome sequence divergence values (≈50% for genera, ≈30% for species) and arbitrarily chosen phenotypic virus or virion characteristics. Here we report filovirus genome sequence-based taxon demarcation criteria using the publicly accessible PAirwise Sequencing Comparison (PASC) tool of the US National Center for Biotechnology Information (Bethesda, MD, USA). Comparison of all available filovirus genomes in GenBank using PASC revealed optimal genus demarcation at the 55–58% sequence diversity threshold range for genera and at the 23–36% sequence diversity threshold range for species. Because these thresholds do not change the current official filovirus classification, these values are now implemented as filovirus taxon demarcation criteria that may solely be used for filovirus classification in case additional data are absent. A near-complete, coding-complete, or complete filovirus genome sequence will now be required to allow official classification of any novel “filovirus.” Classification of filoviruses into existing taxa or determining the need for novel taxa is now straightforward and could even become automated using a presented algorithm/flowchart rooted in RefSeq (type) sequences.
Selective Arterial Calcium Stimulation With Hepatic Venous Sampling in Immune-Mediated Hypoglycemia
Service, F. John, Andrews, James C. , Thompson, Scott M. , Vella, Adrian

Mayo Clinic

Journal of the Endocrine Society | May 4, 2017 | Volume: 1 | Issue: 6 | Pages: 671-675

10.1210/js.2017-00146 | PMID 29264520 Get It

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
Schriber, Jeffrey, Ahn, Kwang Woo , Fei, Mingwei , Costa, Luciano J. , Kharfan-Dabaja, M A, Angel-Diaz, Miguel, Ganguly, Siddharatha, Girnius, Saulius, Hashmi, Shahrukh K. , Pawarode, Attaphol , Vesole, David H. , Wiernik, Peter H. , Wirk, Baldeep , Marks, David I. , Olsson, Richard F. , Usmani, Saad Z. , D’Souza, Anita , Hashmi, Shahrukh, D'Souza, Anita , Hari, Parameswaran , Gale, Robert Peter , Nishihori, Taiga , Mark, Tomer M , Nieto, Yago , Olsson, Richard F , Costa, Luciano J , Usmani, Saad

Mayo Clinic

Cancer | May 4, 2017 | Volume: 123 | Issue: 16 | Pages: 3141-3149

10.1002/cncr.30747 | PMID 28472539 Get It

BACKGROUNDRace/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/ethnicity in the United States.METHODSThe Center for International Blood and Marrow Transplant Research database was used to identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utilization rate (STUR) was derived. Post‐AHCT outcomes were analyzed among patients ages 18 to 75 years who underwent melphalan‐conditioned peripheral cell grafts (N = 24,102).RESULTSThe STUR increased across all groups from 2008 to 2014. The increase was substantially lower among Hispanics (range, 8.6%‐16.9%) and non‐Hispanic blacks (range, 12.2%‐20.5%) compared with non‐Hispanic whites (range, 22.6%‐37.8%). There were 18,046 non‐Hispanic whites, 4123 non‐Hispanic blacks, and 1933 Hispanic patients. The Hispanic group was younger (P < .001). Fewer patients older than 60 years underwent transplantation among Hispanics (39%) and non‐Hispanic blacks (42%) compared with non‐Hispanic whites (56%). A Karnofsky score <90% and a hematopoietic cell transplantation comorbidity index score >3 were more common in non‐Hispanic blacks compared with Hispanic and non‐Hispanic whites (P < .001). More Hispanics (57%) versus non‐Hispanic blacks (54%) and non‐Hispanic whites (52%; P < .001) had stage III disease. More Hispanics (48%) versus non‐Hispanic blacks (45%) and non‐Hispanic whites (44%) had a very good partial response or better before transplantation (P = .005). Race/ethnicity did not impact post‐AHCT outcomes.CONCLUSIONSAlthough the STUR increased, it remained low and was significantly lower among Hispanics followed by non‐Hispanic blacks compared with non‐Hispanic whites. Race/ethnicity did not impact transplantation outcomes. Efforts to increase the rates of transplantation for eligible patients who have MM, with an emphasis on groups that underuse transplantation, are warranted. Cancer 2017;123:3141–9. © 2017 American Cancer Society.
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, Günter U. , Respondek, Gesine , Stamelou, María , Kurz, Carolin , Josephs, Keith A. , Lang, Anthony E. , Mollenhauer, Brit , Müller, Ulrich , Whitwell, Jennifer L. , Arzberger, Thomas, Englund, Elisabet , Gelpí, Ellen , Irwin, David J. , Meissner, Wassilios G. , Pantelyat, Alexander , Rajput, Alex, Swieten, John C. van, Troakes, Claire , Antonini, Angelo , Bordelon, Yvette , Compta, Yaroslau , Corvol, Jean‐Christophe , Dodel, Richard , Ferguson, Leslie W. , Kassubek, Jan , Krismer, Florian , Xiong, Chengjie , Lorenzl, Stefan , Morris, Huw R. , Nestor, Peter J. , Oertel, Wolfgang H., Rabinovici, Gil D. , Rowe, James B. , Schellenberg, Gerard D., Seppi, Klaus , Eimeren, Thilo van , Wenning, Gregor K. , Boxer, Adam L. , Golbe, Lawrence I. , Group, for the Movement Disorder Society–endorsed PSP Study, Meissner, Wassilios G , Bhatia, Kailash P , Nilsson, Christer C. , Giese, Armin , Swieten, John C. van , Bhatia, Kailash P. , Colosimo, Carlo , Dickson, Dennis W. , Grossman, Murray , Krismer, Florian , Poewe, Werner H , Schellenberg, Gerard D., Litvan, Irene , Group, for the Movement Disorder Society–endorsed PSP Study, Höglinger, Günter U , Lang, Anthony E , Irwin, David J , Antonini, Angelo , Rowe, James B , Corvol, Jean-Christophe , Seppi, Klaus , Xiong, Chengjie , Gelpi, Ellen , Pantelyat, Alex , Rabinovici, Gil D , Troakes, Claire , Morris, Huw R , van Eimeren, Thilo

Mayo Clinic

Movement Disorders | May 3, 2017 | Volume: 32 | Issue: 6 | Pages: 853-864

10.1002/mds.26987 | PMID 28467028 Get It

ABSTRACT Background : PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome. Objective : We aimed to provide an evidence‐ and consensus‐based revision of the clinical diagnostic criteria for PSP. Methods : We searched the PubMed, Cochrane, Medline, and PSYCInfo databases for articles published in English since 1996, using postmortem diagnosis or highly specific clinical criteria as the diagnostic standard. Second, we generated retrospective standardized clinical data from patients with autopsy‐confirmed PSP and control diseases. On this basis, diagnostic criteria were drafted, optimized in two modified Delphi evaluations, submitted to structured discussions with consensus procedures during a 2‐day meeting, and refined in three further Delphi rounds. Results : Defined clinical, imaging, laboratory, and genetic findings serve as mandatory basic features, mandatory exclusion criteria, or context‐dependent exclusion criteria. We identified four functional domains (ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction) as clinical predictors of PSP. Within each of these domains, we propose three clinical features that contribute different levels of diagnostic certainty. Specific combinations of these features define the diagnostic criteria, stratified by three degrees of diagnostic certainty (probable PSP, possible PSP, and suggestive of PSP). Clinical clues and imaging findings represent supportive features. Conclusions : Here, we present new criteria aimed to optimize early, sensitive, and specific clinical diagnosis of PSP on the basis of currently available evidence. © 2017 International Parkinson and Movement Disorder Society
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Burris, Howard A. , Infante, Jeffrey R., Ansell, Stephen M. , Weiss, Geoffrey R. , Villalobos, Víctor M. , Šikić, Branimir I. , Northfelt, Donald W. , Carson, William E. , Hawthorne, Thomas, Davis, Thomas A., Yellin, Michael , Keler, Tibor , Infante, Jon , Nemunaitis, John J, Hawthorne, Thomas R, Yellin, Michael J, Bullock, Timothy, Nemunaitis, John , Taylor, Matthew H. , Bullock, Timothy N J , Carson, William E , Infante, Jon

Mayo Clinic

Journal of Clinical Oncology | May 2, 2017 | Volume: 35 | Issue: 18 | Pages: 2028-2036

10.1200/jco.2016.70.1508 | PMID 28463630 Get It

Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors. Methods In a 3 + 3 dose-escalation design (n = 25), patients received a single dose of varlilumab (0.1, 0.3, 1.0, 3.0, or 10 mg/kg intravenously) with a 28-day observation, followed by up to five multidose cycles (one dose per week for 4 weeks), depending on tumor response. Expansion cohorts were initiated at 3.0 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15). Primary objectives were to assess the safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of varlilumab. Results Exposure to varlilumab was linear and dose proportional across dose groups. Only one patient experienced a dose-limiting toxicity—grade 3 transient asymptomatic hyponatremia at the 1.0-mg/kg dose level. Treatment-related adverse events were generally grade 1 or 2 in severity. Evidence of biologic activity consistent with CD27 stimulation—chemokine induction, T-cell stimulation, regulatory T cell depletion—was observed at all dose levels. A patient with metastatic RCC experienced a partial response (78% shrinkage, progression-free survival > 2.3 years). Eight patients experienced stable disease > 3 months, including a patient with metastatic RCC with progression-free survival of > 3.9 years. Conclusion Dose escalation of varlilumab to 10 mg/kg was well tolerated without identification of a maximum tolerated dose. Varlilumab was biologically and clinically active.